Previous 10 | Next 10 |
2023-10-02 17:17:30 ET More on Athersys Athersys shares slide on pricing $3.5 million stock offering Seeking Alpha’s Quant Rating on Athersys Historical earnings data for Athersys Financial information for Athersys For further details see: ...
2023-09-13 17:40:45 ET More on Athersys Seeking Alpha’s Quant Rating on Athersys Historical earnings data for Athersys Financial information for Athersys Athersys shares slide on pricing $3.5 million stock offering For further details see: ...
Athersys, Inc. (Nasdaq: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces that Dr. Samuel Tingle, a surgeon and PhD candidate at Newcastle University in Newcastle upon Tyne, England, has received gra...
2023-08-18 10:09:04 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Applied Materials (NASDAQ: AMAT ) stock is climbing higher on Friday after getting new price targets following its latest earnings report. Morgan Stanley analyst Joseph Moor...
2023-08-18 09:04:02 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Athersys (NASDAQ: ATHX ) stock is falling on Friday after the biotechnology company announced a public stock offering . That public offering has Athersys selling 10,937,...
2023-08-18 02:57:02 ET More on Athersys Athersys restructures debt with supplier, prioritizing multi-stem for stroke treatment Athersys stock rises as FDA accepts changes to phase 3 trial of stroke therapy MultiStem For further details see: Athersys shares slide ...
Athersys, Inc. (Nasdaq: ATHX), today announced the pricing of its “reasonable best efforts” public offering of 10,937,500 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.32 per share. The Company further agreed to issue to the investors...
2023-08-16 17:23:19 ET More on Athersys Athersys restructures debt with supplier, prioritizing multi-stem for stroke treatment Athersys stock slides after launch of $3.7M equity offering Athersys stock rises as FDA accepts changes to phase 3 trial of stroke therapy M...
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and six months ended June 30, 2023 and provided a business update. Second Quarter 2023 and R...
Healthcare Executive and Strategy Consultant Brings Considerable Innovation, Commercialization and Entrepreneurial Expertise Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today the ...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million pri...